Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus KLONOPIN RAPIDLY DISINTEGRATING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus KLONOPIN RAPIDLY DISINTEGRATING.
DORAL vs KLONOPIN RAPIDLY DISINTEGRATING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
15-30 mg orally at bedtime, maximum 60 mg/day.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Category C
Category C
Benzodiazepine
Benzodiazepine